Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review.

Aggressive variants papillary thyroid cancer Columnar cell variant Diffuse sclerosis variant Hobnail variant Solid variant Tall cell variant

Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
07 2020
Historique:
received: 28 04 2020
pubmed: 4 6 2020
medline: 16 2 2021
entrez: 4 6 2020
Statut: ppublish

Résumé

Aggressive variants of papillary thyroid cancer (PTC) have been described with increasing frequency. These variants include diffuse sclerosing variant, tall cell variant, columnar cell variant, solid variant, and hobnail variant. We have performed a review of the more aggressive variants of PTC with respect to main characteristics, histological and molecular features, and the consequences that the knowledge of these variants should have in the treatment of the patients. At the present time, we do not know the prognostic value of these aggressive PTC variants. The extent of the surgical treatment and adjuvant therapy necessary should be decided on the basis of the extent of the tumor at presentation and the opinion of experienced clinicians. These aggressive variants should be known by clinicians, to avoid underdiagnosis, and treated according to the latest recommendations in the literature.

Identifiants

pubmed: 32488657
doi: 10.1007/s12325-020-01391-1
pii: 10.1007/s12325-020-01391-1
pmc: PMC7467416
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

3112-3128

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Références

Lloyd R, Osamura R, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer; 2017.
Clark OH. Thyroid cancer and lymph node metastases. J Surg Oncol. 2011;103:615–8.
pubmed: 21480256 doi: 10.1002/jso.21804
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.
pubmed: 4739132 pmcid: 4739132 doi: 10.1089/thy.2015.0020
Lam AK-Y, Lo C-Y, Lam KS-L. Papillary carcinoma of thyroid: a 30-year clinicopathological review of the histological variants. Endocr Pathol. 2005;16:323–30.
pubmed: 16627919 doi: 10.1385/EP:16:4:323
Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg. 2007;31:916–23.
pubmed: 17345120 doi: 10.1007/s00268-006-0837-3
Vickery AL, Carcangiu ML, Johannessen JV, Sobrinho-Simoes M. Papillary carcinoma. Semin Diagn Pathol. 1985;2:90–100.
pubmed: 3843693
Chow S-M, Chan JKC, Law SCK, et al. Diffuse sclerosing variant of papillary thyroid carcinoma—clinical features and outcome. Eur J Surg Oncol. 2003;29:446–9.
pubmed: 12798749 doi: 10.1016/S0748-7983(03)00005-2
Pillai S, Gopalan V, Smith RA, Lam AK-Y. Diffuse sclerosing variant of papillary thyroid carcinoma—an update of its clinicopathological features and molecular biology. Crit Rev Oncol Hematol. 2015;94:64–73.
pubmed: 25577570 doi: 10.1016/j.critrevonc.2014.12.001
Lam AKY, Lo CY. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol. 2006;13:176–81.
pubmed: 16411146 doi: 10.1245/ASO.2006.03.062
Falvo L, Giacomelli L, D’Andrea V, Marzullo A, Guerriero G, de Antoni E. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg. 2006;72:438–44.
pubmed: 16719201
Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol. 2012;19:1874–80.
pubmed: 22065195 doi: 10.1245/s10434-011-2129-x
Fridman MV, Savva NN, Krasko OV, et al. Clinical and pathologic features of “sporadic” papillary thyroid carcinoma registered in the years 2005 to 2008 in children and adolescents of Belarus. Thyroid. 2012;22:1016–24.
pubmed: 22947350 doi: 10.1089/thy.2011.0005
Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl disaster. Pathomorphologic study of 84 cases (1991–1992) from the Republic of Belarus. Cancer. 1994;74:748–66.
pubmed: 8033057 doi: 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H
Regalbuto C, Malandrino P, Tumminia A, Le Moli R, Vigneri R, Pezzino V. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid. 2011;21:383–9.
pubmed: 21309722 doi: 10.1089/thy.2010.0331
Vuong HG, Kondo T, Pham TQ, et al. Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol. 2017;176:433–41.
pubmed: 28183787 doi: 10.1530/EJE-16-0863
Takagi N, Hirokawa M, Nobuoka Y, Higuchi M, Kuma S, Miyauchi A. Diffuse sclerosing variant of papillary thyroid carcinoma: a study of fine needle aspiration cytology in 20 patients. Cytopathology. 2014;25:199–204.
pubmed: 23781895 doi: 10.1111/cyt.12076
Koo JS, Shin E, Hong SW. Immunohistochemical characteristics of diffuse sclerosing variant of papillary carcinoma: comparison with conventional papillary carcinoma. APMIS. 2010;118:744–52.
pubmed: 20854468 doi: 10.1111/j.1600-0463.2010.02653.x
Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck. 2011;33:1052–9.
pubmed: 20824810 doi: 10.1002/hed.21494
Sheu S-Y, Schwertheim S, Worm K, Grabellus F, Schmid KW. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol. 2007;20:779–87.
pubmed: 17464312 doi: 10.1038/modpathol.3800797
Joung JY, Kim TH, Jeong DJ, et al. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications. Histopathology. 2016;69:45–53.
pubmed: 26568156 doi: 10.1111/his.12902
Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK-Y. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol. 2011;42:500–6.
pubmed: 21167555 doi: 10.1016/j.humpath.2009.09.023
Lin X, Finkelstein SD, Zhu B, Silverman JF. Molecular analysis of multifocal papillary thyroid carcinoma. J Mol Endocrinol. 2008;41:195–203.
pubmed: 18628356 doi: 10.1677/JME-08-0063
Lee J-H, Lee ES, Kim Y-S, Won NH, Chae Y-S. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology. 2006;38:201–4.
pubmed: 16753739 doi: 10.1080/00313020600696264
Lim JY, Hong SW, Lee YS, et al. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid. 2013;23:1423–30.
pubmed: 23496275 doi: 10.1089/thy.2013.0036
Asioli S, Erickson LA, Sebo TJ, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010;34:44–52.
pubmed: 19956062 doi: 10.1097/PAS.0b013e3181c46677
Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844–50.
pubmed: 22592144 doi: 10.1097/PAS.0b013e318246b527
Sheu S-Y, Grabellus F, Schwertheim S, Handke S, Worm K, Schmid KW. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma. Horm Metab Res. 2009;41:482–7.
pubmed: 19370505 doi: 10.1055/s-0029-1215558
Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q. 1976;43:207–15.
pubmed: 1000814 doi: 10.3949/ccjm.43.4.207
Crile G, Hazard JB, Dinsmore RS. Carcinoma of the thyroid gland, with special reference to a clinicopathologic classification. J Clin Endocrinol Metab. 1948;8:762–5.
pubmed: 18880944 doi: 10.1210/jcem-8-9-762
Ganly I, Ibrahimpasic T, Rivera M, et al. Prognostic implications of papillary thyroid carcinoma with tall-cell features. Thyroid. 2014;24:662–70.
pubmed: 24262069 doi: 10.1089/thy.2013.0503
Beninato T, Scognamiglio T, Kleiman DA, et al. Ten percent tall cells confer the aggressive features of the tall cell variant of papillary thyroid carcinoma. Surgery. 2013;154:1331–6.
pubmed: 24238051 doi: 10.1016/j.surg.2013.05.009
Oh WJ, Lee YS, Cho U, et al. Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features. Korean J Pathol. 2014;48:201–8.
pubmed: 25013418 pmcid: 4087133 doi: 10.4132/KoreanJPathol.2014.48.3.201
LiVolsi VA. Papillary carcinoma tall cell variant (TCV): a review. Endocr Pathol. 2010;21:12–5.
pubmed: 20174895 doi: 10.1007/s12022-010-9106-y
Wang X, Cheng W, Liu C, Li J. Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. Oncotarget. 2016;7:40792–9.
pubmed: 27008708 pmcid: 5130045 doi: 10.18632/oncotarget.8215
Gunalp B, Okuyucu K, Ince S, Ayan A, Alagoz E. Impact of tall cell variant histology on predicting relapse and changing the management of papillary thyroid carcinoma patients. Hell J Nucl Med. 2017;20:122–7.
pubmed: 28697188
Morris LGT, Shaha AR, Tuttle RM, Sikora AG, Ganly I. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid. 2010;20:153–8.
pubmed: 20151822 pmcid: 3714453 doi: 10.1089/thy.2009.0352
Nath MC, Erickson LA. Aggressive variants of papillary thyroid carcinoma: hobnail, tall cell, columnar, and solid. Adv Anat Pathol. 2018;25:172–9.
pubmed: 29351089 doi: 10.1097/PAP.0000000000000184
Russo M, Malandrino P, Moleti M, et al. Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods. J Endocrinol Invest. 2017;40:1235–41.
pubmed: 28528434 doi: 10.1007/s40618-017-0688-9
Vuong HG, Long NP, Anh NH, et al. Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: a meta-analysis. Endocr Connect. 2018;7:R286–93.
pubmed: 30352403 pmcid: 6240142 doi: 10.1530/EC-18-0333
Bongers PJ, Kluijfhout WP, Verzijl R, et al. Papillary thyroid cancers with focal tall cell change are as aggressive as tall cell variants and should not be considered as low-risk disease. Ann Surg Oncol. 2019;26:2533–9.
pubmed: 31115855 doi: 10.1245/s10434-019-07444-2
Wong KS, Higgins SE, Marqusee E, Nehs MA, Angell T, Barletta JA. Tall cell variant of papillary thyroid carcinoma: impact of change in WHO definition and molecular analysis. Endocr Pathol. 2019;30:43–8.
pubmed: 30565013 doi: 10.1007/s12022-018-9561-4
Hernandez-Prera JC, Machado RA, Asa SL, et al. Pathologic reporting of tall-cell variant of papillary thyroid cancer: have we reached a consensus? Thyroid. 2017;27:1498–504.
pubmed: 29020884 doi: 10.1089/thy.2017.0280
Solomon A, Gupta PK, LiVolsi VA, Baloch ZW. Distinguishing tall cell variant of papillary thyroid carcinoma from usual variant of papillary thyroid carcinoma in cytologic specimens. Diagn Cytopathol. 2002;27:143–8.
pubmed: 12203860 doi: 10.1002/dc.10156
Das DK, Mallik MK, Sharma P, et al. Papillary thyroid carcinoma and its variants in fine needle aspiration smears. A cytomorphologic study with special reference to tall cell variant. Acta Cytol. 2004;48:325–36.
pubmed: 15192947 doi: 10.1159/000326381
Erler P, Keutgen XM, Crowley MJ, et al. Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer. Surgery. 2014;156:1342–50 (discussion 1350).
pubmed: 25456905 doi: 10.1016/j.surg.2014.08.007
Basolo F, Giannini R, Monaco C, et al. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol. 2002;160:247–54.
pubmed: 11786418 pmcid: 1867131 doi: 10.1016/S0002-9440(10)64368-4
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–90.
doi: 10.1016/j.cell.2014.09.050
Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol. 2004;86:44–54.
pubmed: 15048680 doi: 10.1002/jso.20044
Gaertner EM, Davidson M, Wenig BM. The columnar cell variant of thyroid papillary carcinoma. Case report and discussion of an unusually aggressive thyroid papillary carcinoma. Am J Surg Pathol. 1995;19:940–7.
pubmed: 7611541 doi: 10.1097/00000478-199508000-00010
Sujoy V, Pinto A, Nosé V. Columnar cell variant of papillary thyroid carcinoma: a study of 10 cases with emphasis on CDX2 expression. Thyroid. 2013;23:714–9.
pubmed: 23488912 doi: 10.1089/thy.2012.0455
Enriquez ML, Baloch ZW, Montone KT, Zhang PJ, LiVolsi VA. CDX2 expression in columnar cell variant of papillary thyroid carcinoma. Am J Clin Pathol. 2012;137:722–6.
pubmed: 22523209 doi: 10.1309/AJCPXE3PUBWVZCGZ
Wenig BM, Thompson LD, Adair CF, Shmookler B, Heffess CS. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. Cancer. 1998;82:740–53.
pubmed: 9477108 doi: 10.1002/(SICI)1097-0142(19980215)82:4<740::AID-CNCR18>3.0.CO;2-Y
Cho J, Shin JH, Hahn SY, Oh YL. Columnar cell variant of papillary thyroid carcinoma: ultrasonographic and clinical differentiation between the indolent and aggressive types. Korean J Radiol. 2018;19:10–5.
doi: 10.3348/kjr.2018.19.5.1000
Chen J-H, Faquin WC, Lloyd RV, Nosé V. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Mod Pathol. 2011;24:739–49.
pubmed: 21358618 doi: 10.1038/modpathol.2011.2
Wang S, Xiong Y, Zhao Q, Song H, Yi P, Liu C. Columnar cell papillary thyroid carcinoma prognosis: findings from the SEER database using propensity score matching analysis. Am J Transl Res. 2019;11:6262–70.
pubmed: 31632592 pmcid: 6789210
Jiang C, Cheng T, Zheng X, et al. Clinical behaviors of rare variants of papillary thyroid carcinoma are associated with survival: a population-level analysis. Cancer Manag Res. 2018;10:465–72.
pubmed: 29563836 pmcid: 5849916 doi: 10.2147/CMAR.S157823
Bongiovanni M, Mermod M, Canberk S, et al. Columnar cell variant of papillary thyroid carcinoma: cytomorphological characteristics of 11 cases with histological correlation and literature review. Cancer Cytopathol. 2017;125:389–97.
pubmed: 28374549 doi: 10.1002/cncy.21860
Rottuntikarn W, Wangsiricharoen S, Rangdaeng S. Cytomorphology and immunocytochemistry of columnar cell variant of papillary thyroid carcinoma. Cytopathology. 2017;28:338–41.
pubmed: 28470960 doi: 10.1111/cyt.12429
Sak SD. Variants of papillary thyroid carcinoma: multiple faces of a familiar tumor. Turk Patol Derg. 2015;31(Suppl 1):34–47.
Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer. 1985;55:805–28.
pubmed: 3967175 doi: 10.1002/1097-0142(19850215)55:4<805::AID-CNCR2820550419>3.0.CO;2-Z
Damle N, Ramya S, Bal C, Durgapal P. Solid variant of papillary carcinoma thyroid in a child with no history of radiation exposure. Indian J Nucl Med. 2011;26:196–8.
pubmed: 23559717 pmcid: 3613628 doi: 10.4103/0972-3919.106707
Chang H, Kim SM, Chun KW, et al. Clinicopathologic features of solid variant papillary thyroid cancer. ANZ J Surg. 2014;84:380–2.
pubmed: 23826897 doi: 10.1111/ans.12307
Guleria P, Phulware R, Agarwal S, et al. Cytopathology of solid variant of papillary thyroid carcinoma: differential diagnoses with other thyroid tumors. Acta Cytol. 2018;62:371–9.
pubmed: 30253413 doi: 10.1159/000493081
Sebastian SO, Gonzalez JM, Paricio PP, et al. Papillary thyroid carcinoma: prognostic index for survival including the histological variety. Arch Surg. 2000;135:272–7.
pubmed: 10722027 doi: 10.1001/archsurg.135.3.272
Vander Poorten V, Hens G, Delaere P. Thyroid cancer in children and adolescents. Curr Opin Otolaryngol Head Neck Surg. 2013;21:135–42.
pubmed: 23486378 doi: 10.1097/MOO.0b013e32835e15d9
Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol. 2011;5:51–6.
pubmed: 21221869 pmcid: 3037461 doi: 10.1007/s12105-010-0236-9
Vuong HG, Odate T, Duong UNP, et al. Prognostic importance of solid variant papillary thyroid carcinoma: a systematic review and meta-analysis. Head Neck. 2018;40:1588–97.
pubmed: 29509280 doi: 10.1002/hed.25123
Ohashi R, Kawahara K, Namimatsu S, et al. Clinicopathological significance of a solid component in papillary thyroid carcinoma. Histopathology. 2017;70:775–81.
pubmed: 27882585 doi: 10.1111/his.13132
Ohashi R, Murase Y, Matsubara M, et al. Fine needle aspiration cytology of the papillary thyroid carcinoma with a solid component: a cytological and clinical correlation. Diagn Cytopathol. 2017;45:391–8.
pubmed: 28224716 doi: 10.1002/dc.23679
Trovisco V, Soares P, Soares R, Magalhães J, Sá-Couto P, Sobrinho-Simões M. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol. 2005;36:694–7.
pubmed: 16021577 doi: 10.1016/j.humpath.2005.04.011
Kakudo K, Tang W, Ito Y, Mori I, Nakamura Y, Miyauchi A. Papillary carcinoma of the thyroid in Japan: subclassification of common type and identification of low risk group. J Clin Pathol. 2004;57:1041–6.
pubmed: 15452157 pmcid: 1770442 doi: 10.1136/jcp.2004.017889
Motosugi U, Murata S-I, Nagata K, Yasuda M, Shimizu M. Thyroid papillary carcinoma with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy? Thyroid. 2009;19:535–7.
pubmed: 19348583 doi: 10.1089/thy.2008.0271
Asioli S, Erickson LA, Righi A, Lloyd RV. Papillary thyroid carcinoma with hobnail features: histopathologic criteria to predict aggressive behavior. Hum Pathol. 2013;44:320–8.
pubmed: 23036367 doi: 10.1016/j.humpath.2012.06.003
Lubitz CC, Economopoulos KP, Pawlak AC, et al. Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. Thyroid. 2014;24:958–65.
pubmed: 24417340 pmcid: 4046200 doi: 10.1089/thy.2013.0573
Amacher AM, Goyal B, Lewis JS, El-Mofty SK, Chernock RD. Prevalence of a hobnail pattern in papillary, poorly differentiated, and anaplastic thyroid carcinoma: a possible manifestation of high-grade transformation. Am J Surg Pathol. 2015;39:260–5.
pubmed: 25321328 doi: 10.1097/PAS.0000000000000329
Asioli S, Maletta F, Pagni F, et al. Cytomorphologic and molecular features of hobnail variant of papillary thyroid carcinoma: case series and literature review. Diagn Cytopathol. 2014;42:78–84.
pubmed: 23913779 doi: 10.1002/dc.23028
Morandi L, Righi A, Maletta F, et al. Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma. Endocr Relat Cancer. 2017;24:107–17.
pubmed: 28062544 doi: 10.1530/ERC-16-0546
Ambrosi F, Righi A, Ricci C, Erickson LA, Lloyd RV, Asioli S. Hobnail variant of papillary thyroid carcinoma: a literature review. Endocr Pathol. 2017;28:293–301.
pubmed: 29019044 doi: 10.1007/s12022-017-9502-7
Wong KS, Chen TY, Higgins SE, et al. A potential diagnostic pitfall for hobnail variant of papillary thyroid carcinoma. Histopathology. 2019;76:707–13.
doi: 10.1111/his.14042
Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008;113:48–56.
pubmed: 18484584 doi: 10.1002/cncr.23515
Malandrino P, Russo M, Regalbuto C, et al. Outcome of the diffuse sclerosing variant of papillary thyroid cancer: a meta-analysis. Thyroid. 2016;26:1285–92.
pubmed: 27349273 doi: 10.1089/thy.2016.0168
Yamashita H, Noguchi S, Takahashi H, et al. The diffuse sclerosing variant of papillary thyroid carcinoma is not an aggressive subtype of papillary carcinoma. J Thyroid Disord Ther. 2014;3:163.
Limberg J, Ullmann TM, Stefanova D, et al. Does aggressive variant histology without invasive features predict overall survival in papillary thyroid cancer? A National Cancer Database Analysis. Ann Surg. 2019. https://doi.org/10.1097/SLA.0000000000003632 .

Auteurs

Andrés Coca-Pelaz (A)

Department of Otolaryngology, Hospital Universitario Central de Asturias-University of Oviedo, Oviedo, Asturias, Spain. acocapelaz@yahoo.es.
Instituto de Investigación Sanitaria del Principado de Asturias, IUOPA, CIBERONC, Oviedo, Asturias, Spain. acocapelaz@yahoo.es.

Jatin P Shah (JP)

Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Juan C Hernandez-Prera (JC)

Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.

Ronald A Ghossein (RA)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Juan P Rodrigo (JP)

Department of Otolaryngology, Hospital Universitario Central de Asturias-University of Oviedo, Oviedo, Asturias, Spain.
Instituto de Investigación Sanitaria del Principado de Asturias, IUOPA, CIBERONC, Oviedo, Asturias, Spain.

Dana M Hartl (DM)

Division of Surgical Oncology, Gustave Roussy Cancer Center and Paris-Sud University, Villejuif Cedex, Paris, France.

Kerry D Olsen (KD)

Department of Otorhinolaryngology, Mayo Clinic, Rochester, MN, USA.

Ashok R Shaha (AR)

Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Mark Zafereo (M)

Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Carlos Suarez (C)

Instituto de Investigación Sanitaria del Principado de Asturias, IUOPA, CIBERONC, Oviedo, Asturias, Spain.

Iain J Nixon (IJ)

Department of Surgery and Otolaryngology, Head and Neck Surgery, Edinburgh University, Edinburgh, Scotland, UK.

Gregory W Randolph (GW)

Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Antti A Mäkitie (AA)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Luiz P Kowalski (LP)

Head and Neck Surgery and Otorhinolaryngology Department, A C Camargo Cancer Center, São Paulo, Brazil.

Vincent Vander Poorten (V)

Section Head and Neck Oncology, Otorhinolaryngology-Head and Neck Surgery and Department of Oncology, University Hospitals Leuven, KU Leuven, Louvain, Belgium.

Alvaro Sanabria (A)

Department of Surgery, School of Medicine, Universidad de Antioquia/Hospital Universitario San Vicente Fundación-CEXCA Centro de Excelencia en Enfermedades de Cabeza y Cuello, Medellín, Colombia.

Orlando Guntinas-Lichius (O)

Department of Otorhinolaryngology, Institute of Phoniatry/Pedaudiology, Jena University Hospital, Jena, Germany.

Ricard Simo (R)

Head and Neck Cancer Unit, Guy's and St Thomas' Hospital NHS Foundation Trust London, London, UK.

Peter Zbären (P)

Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital, Berne, Switzerland.

Peter Angelos (P)

Department of Surgery, University of Chicago Medical Center, Chicago, IL, USA.

Avi Khafif (A)

Head and Neck Surgery and Oncology Unit, A.R.M. Center for Advanced Otolaryngology Head and Neck Surgery, Assuta Medical Center, Tel Aviv, Israel.

Alessandra Rinaldo (A)

University of Udine School of Medicine, Udine, Italy.

Alfio Ferlito (A)

Coordinator of the International Head and Neck Scientific Group, Padua, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH